Lisata Therapeutics, Inc. has successfully secured stockholder approval for its 2026 Equity Incentive Plan and Employee Stock Purchase Plan during its annual meeting held on November 9, 2026. This approval is significant as it demonstrates the company’s commitment to enhancing employee engagement and retention through equity incentives.

The 2026 Equity Incentive Plan includes an initial reserve of 44,764,472 shares of the company’s common stock. Additionally, the plan will automatically increase the number of shares reserved each January 1 by 5% of the outstanding shares from the previous year. The Employee Stock Purchase Plan has an initial reserve of 3,730,372 shares and will also see annual increases starting January 1, 2027.

Lisata Therapeutics operates within the pharmaceutical preparations industry, which is characterized by its competitive landscape for talent. Companies in this sector are increasingly adopting similar strategies to attract and retain skilled employees. Competitors like Moderna and BioNTech are also known for their robust employee equity programs, highlighting the importance of such initiatives in the industry.

During the annual meeting, stockholders voted on several proposals, with seven out of eight proposals being approved. Notably, the election of Cynthia L. Flowers and Dr. Ted W. Love, M.D., to the Board of Directors was confirmed, with significant support from shareholders. The meeting was adjourned regarding Proposal No. 3, which concerns the issuance of shares related to the conversion of the company’s Series C Non-Voting Convertible Preferred Stock.

A total of 10,804,066 shares of common stock were outstanding as of the record date, with 8,172,668 shares, or 75.64%, present or represented by proxy at the meeting. The results of the voting on the proposals reflect strong support from the stockholders.

The company’s board had previously approved the 2026 Equity Incentive Plan and the Employee Stock Purchase Plan on October 7, 2026, pending stockholder approval. The comprehensive nature of these plans indicates Lisata Therapeutics’ strategic focus on fostering a motivated workforce.

Looking ahead, the annual meeting will reconvene on November 30, 2026, to address the Conversion Proposal. The company plans to report the voting results on this proposal in a future filing.

For more details on the proposals and their implications, the company’s definitive proxy statement filed on October 19, 2026, provides further insights.